Serious Infection Risk in Pediatric Psoriasis with Ustekinumab, Etanercept, or MTX This comparative analysis looks at t

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Serious Infection Risk in Pediatric Psoriasis with Ustekinumab, Etanercept, or MTX This comparative analysis looks at the risk of SIE requiring hospitalization in pediatric PSO patients treated with ustekinumab, etanercept, or MTX prior to 2016. https://t.co/kR14nrZzCo https://t.co/ccFJcO0eAj
Links
https://bit.ly/3xaQFLH
Show on Archive Page
On
Display in Search Results
On
PDQ
Off

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.